［1］Aslam N，Marino CR.Malignant ascites：New concepts in pathophysiology，diagnosis，and management［J］.Arch Intern Med，2001，10-24(22)：2733-2737.
［2］Okines A，Verheij M，Allum W，et al.Gastric cancer：ESMO clinical practice guidelines for diagnosis，treatment and follow-up［J］.Ann Oncol，2010，21(Suppl 5)：v50-54.
［3］Fang FQ，Song XX，Guo HS，et al.Clinical observation of recombinant human vascular endotheliostatin combined with 5-FU/DDP sequential intraperitoneal injection in the treatment of malignant ascites of gastric cancer［J］.Chinese Journal of Modern Medicine，2014，24(33)：23-26.
［4］Wu Y，Pan M，Cui S，et al.Efficacy and safety of ultrasound-guided continuous hyperthermic intraperitoneal perfusionchemotherapy for the treatment of malignant ascites：A midterm study of 36 patients［J］.Onco Targets Ther，2016，20(9)：403-407.
［5］Ni X，Wu P，Wu J，et al.Hyperthermic intraperitoneal perfusion chemotherapy and response evaluation in patients with gastric cancer and malignant ascites［J］.Oncol Lett，2017，14(2)：1691-1696.
［6］Roviello F，Caruso S，Marrelli D，et al.Treatment of peritoneal carcinomatosis with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy：State of the art and future developments［J］.Surg Oncol，2011，20(1)：e38-54.
［7］Liang R，Lin Y，Li Y，et al.Seven-day capecitabine plus?docetaxel?and oxaliplatin regimen for the treatment of advanced gastric cancer：A phase-I clinical trial［J］.Mol Clin Oncol，2017，6(4)：622-626.
［8］Marchettini P，Stuart OA，Mohamed F，et al.Docetaxel：Pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model［J］.Cancer Chemother Pharmacol，2002，49(6)：499-503.
［9］Wu HT，Peng KW，Ji ZH，et al.Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel to treat synchronous peritoneal carcinomatosis from gastric cancer：Results from a Chinese center［J］.Eur J Surg Oncol，2016，42(7)：1024-1034.
［10］Bing YH，Zheng HP，Lan D，et al.Comparative study of SOX combined with docetaxel intraperitoneal perfusion and DOS regimen in the first-line treatment of advanced gastric cancer with cancerous ascites［J］.Chinese Journal of Cancer Prevention and Treatment，2016，23(16)：1085-1089.
［11］Do JY，Kim YL，Park JW，et al.The association between the vascular endothelial growth factor-to-cancer antigen 125 ratio in peritoneal dialysis effluent and the epithelial-to-mesenchymal transition in continuous ambulatory peritoneal dialysis［J］.Perit Dial Int，2008，28(Suppl 3)：S101-106.
［12］Gamblin V，Da Silva A，Villet S，et al.Supportive care for malignant ascites in palliative phase：Place of paracentesis and diuretics［J］.Bulletin du Cancer，2015，102(11)：940-945.
［13］Zhan N，Dong WG，Wang J.The clinical significance of vascular endothelial growth factor in malignant ascites［J］.Tumour Biol，2016，37(3)：3719-3725.
［14］Wei H，Qin S，Yin X，et al.Endostar inhibits ascites formation and prolongs survival in mouse models of malignant ascites［J］.Oncol Lett，2015，9(6)：2694-2700.
［15］Gremonprez F，Descamps B，Izmer A，et al.Pretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure，increases intraperitoneal chemotherapy drug penetration，and impedes tumor growth in a mouse colorectal carcinomatosis model［J］.Oncotarget，2015，6(30)：29889-29900.
［16］Zhao WY，Chen DY，Chen JH，et al.Effects of intracavitary administration of Endostar combined with cisplatin in malignant pleural effusion and ascites［J］.Cell Biochem Biophys，2014，70(1)：623-628.